Cellectis (CLLS) Net Income towards Common Stockholders (2015 - 2026)
Cellectis (CLLS) recorded quarterly Net Income towards Common Stockholders of -$8.8 million in Q1 2026, up 66.45% quarter-over-quarter from -$26.3 million in Q4 2025, and up 51.29% on a YoY basis from -$5.8 million in Q1 2025.
Cellectis (CLLS) Net Income towards Common Stockholders (2015 - 2026) Analysis & Trends
Cellectis' Net Income towards Common Stockholders history runs 12 years deep, the most recent figure standing at -$8.8 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 51.29% year-over-year to -$8.8 million; the TTM figure through Mar 2026 stood at -$58.3 million (up 3.7% YoY), while the FY2025 annual figure was -$67.6 million, down 83.87% from the prior year.
- Net Income towards Common Stockholders was -$8.8 million for Q1 2026 at Cellectis, up from -$26.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $5.9 million in Q4 2024 to a low of -$41.8 million in Q4 2023.
- Historically, Net Income towards Common Stockholders has averaged -$18.8 million across 5 years, with a median of -$23.1 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders surged 118.76% in 2024, then tumbled 544.41% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$26.8 million in 2022, then sank by 55.86% to -$41.8 million in 2023, then soared by 114.17% to $5.9 million in 2024, then sank by 544.41% to -$26.3 million in 2025, then soared by 66.45% to -$8.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$8.8 million (Q1 2026), -$26.3 million (Q4 2025), and $589000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -8.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.83 Mn |
| Dec 31, 2025 | -26.32 Mn |
| Sep 30, 2025 | 589,000.00 |
| Jun 30, 2025 | -23.74 Mn |
| Mar 31, 2025 | -18.13 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | -23.06 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Mar 31, 2024 | 5.64 Mn |
| Dec 31, 2023 | -41.80 Mn |
| Sep 30, 2023 | -17.48 Mn |
| Jun 30, 2023 | -11.71 Mn |
| Mar 31, 2023 | -30.07 Mn |
| Dec 31, 2022 | -26.82 Mn |
| Sep 30, 2022 | -28.47 Mn |
| Jun 30, 2022 | -18.95 Mn |
| Mar 31, 2022 | -31.91 Mn |
| Dec 31, 2021 | -25.00 Mn |
| Sep 30, 2021 | -37.41 Mn |
| Jun 30, 2021 | -39.92 Mn |